<DOC>
	<DOCNO>NCT01302899</DOCNO>
	<brief_summary>The study design primarily assess effect aliskiren albuminuria patient non-diabetic nephropathy treat ramipril volume intervention .</brief_summary>
	<brief_title>To Study Effects Aliskiren Albuminuria Various Biomarkers Patients With Nephropathy</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Albuminuria</mesh_term>
	<mesh_term>Ramipril</mesh_term>
	<mesh_term>Hydrochlorothiazide</mesh_term>
	<criteria>Male female subject , age 18 year Patients chronic kidney disease nondiabetic origin Glomerular filtration rate &gt; 30 ml/min/1.73m2 Patients history hypertension msSBP ( mean systolic blood pressure ) &lt; 160 mm Hg msDBP ( mean diastolic blood pressure ) &lt; 105 mm Hg screen baseline . Subjects must body mass index ( BMI ) within range 18 35 kg/m2 Previously treat ( within 3 month screen ) aliskiren combination aliskiren ramipril . Severe hypertension ( msDBP ≥110 mmHg msSBP ≥180 mmHg ) Pregnant nursing ( lactate ) woman , A medical history unstable coronary artery disease , myocardial infarction , coronary bypass surgery cerebrovascular accident within last six ( 6 ) month Diabetes mellitus , Heart failure High rate renal function loss History severe hypersensitivity contraindication medication drug belong similar therapeutic class study drug excipients . History liver disease , positive Hepatitis B surface antigen ( HBsAg ) Hepatitis C test result History immunodeficiency disease , include positive HIV ( ELISA Western blot ) test result . Other protocoldefined inclusion/exclusion criterion apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
</DOC>